ArticleStem cell research & therapy2025
Umbilical cord mesenchymal stem cells protect against obstetric deep venous thrombosis in rats by suppressing ferroptosis.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe objective of the current investigation is to explore the role of ferroptosis in mediating the protective effects associated with umbilical cord mesenchymal stem cells (UCMSCs) on obstetric deep venous thrombosis (DVT) in vivo and in vitro.
methodsA pregnant rat model of DVT was created through the application of a "stenosis" technique targeting the inferior vena cava (IVC). Furthermore, the protective effects of UCMSCs were evaluated on pregnant rats with DVT and impaired endothelial cells. Subsequently, transcriptome sequencing was utilized to pinpoint the genes that exhibited differential expression in the thrombosed IVC tissues of rats belonging to both the DVT) and DVT + UCMSC groups. Finally, the role of the candidate gene was demonstrated.
resultsThe administration of UCMSCs into pregnant rats diagnosed with DVT notably led to a greater degree of angiogenesis, alleviated coagulation, inflammation, and ferroptosis, and ameliorated the pregnancy outcomes. In vitro, erastin induced typical features related to ferroptosis. UCMSC-conditioned medium (UC-CM) effectively enhanced the capacity of dysfunctional endothelial cells to undergo proliferation, migration, invasion, and the formation of vessel-like structures, and normalized the levels of reactive oxygen species and malondialdehyde. The analysis of KEGG pathway enrichment revealed that the signaling pathway associated with ferroptosis in the thrombosed tissues of rats in the UCMSC group markedly suppressed. The levels of arachidonate-15-lipoxygenase (ALOX15), a marker related to ferroptosis, was significantly downregulated in both thrombosed tissues and endothelial cells sorted out from these tissues after UCMSC transplantation. Furthermore, the function of ALOX15 was verified in vitro and in vivo. In conclusion, this study suggested that UCMSCs mitigated the inflammation levels, facilitated recanalization, and improved pregnancy outcomes in cases of obstetric DVT by mitigating ferroptosis within endothelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.